RNA Therapeutics for Renal Fibrosis: Mechanisms, Clinical Insights, and Emerging Advances

Abstract

Renal fibrosis is a final common pathway in chronic kidney disease (CKD), leading to progressive loss of renal function and eventually end-stage kidney disease (ESKD). Despite advances in understanding its multifactorial pathogenesis, therapeutic options remain limited, especially in targeting the underlying molecular and cellular mechanisms. Recently, RNA therapeutics, including small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and microRNA (miRNA) modulators, have emerged as promising modalities to interrupt fibrogenic pathways at the genetic level. This review provides a comprehensive overview of RNA-based therapies for renal fibrosis, discussing their mechanisms, preclinical and clinical findings, and the challenges and opportunities for translation into clinical practice.

Introduction

Renal fibrosis is a key determinant of CKD progression, characterized by excessive deposition of extracellular matrix (ECM) components, tubular atrophy, and glomerulosclerosis. The lack of effective anti-fibrotic therapies necessitates the exploration of novel strategies. RNA therapeutics offer a targeted approach by modulating gene expression involved in fibrogenesis, with the potential to alter disease trajectory. This article synthesizes current evidence on the use of RNA therapeutics in renal fibrosis, focusing on clinical relevance, recent advances, and future directions.

Epidemiology / Disease Burden

CKD affects approximately 10% of the global population, with renal fibrosis representing the pathological hallmark in almost all progressive forms. The burden of CKD-related morbidity and mortality is rising, driven by aging populations and increasing prevalence of diabetes and hypertension. Renal fibrosis is strongly associated with adverse renal outcomes, cardiovascular events, and increased healthcare costs. The unmet need for disease-modifying therapies in this context underscores the significance of RNA-based approaches.

Pathophysiology

The pathogenesis of renal fibrosis involves a complex interplay of cellular and molecular events. Key processes include activation of renal fibroblasts and pericytes, epithelial-to-mesenchymal transition (EMT), persistent inflammation, and dysregulated signaling pathways such as TGF-β/Smad, Wnt/β-catenin, and Notch. These culminate in excessive ECM accumulation, progressive nephron loss, and impairment of renal architecture. RNA therapeutics aim to silence, degrade, or modulate the expression of key profibrotic mediators, thereby interrupting these pathogenic cascades at the transcriptomic level.

Risk Factors

Major risk factors for renal fibrosis include chronic hyperglycemia, hypertension, persistent proteinuria, recurrent urinary tract infections, and exposure to nephrotoxins. Genetic susceptibility, older age, and male sex also contribute. Importantly, subclinical inflammation, uremic milieu, and metabolic derangements perpetuate fibrogenesis, highlighting the need for interventions targeting both systemic and local renal factors.

Clinical Features

Renal fibrosis itself is a histopathological diagnosis, often inferred from clinical manifestations of CKD, including proteinuria, reduced glomerular filtration rate (GFR), hypertension, and progressive azotemia. Advanced fibrosis may be associated with refractory edema, anemia, mineral bone disorder, and uremic symptoms. Imaging and laboratory assessment aid in staging disease severity but lack specificity for fibrosis burden.

Diagnosis

Definitive diagnosis of renal fibrosis is based on renal biopsy, demonstrating interstitial expansion, collagen deposition, tubular atrophy, and glomerulosclerosis. However, biopsy is invasive and not routinely performed. Non-invasive biomarkers such as urinary TGF-β1, connective tissue growth factor (CTGF), and microRNAs (e.g., miR-21, miR-29) are under investigation. Advanced imaging modalities, including MRI-based elastography and diffusion tensor imaging, offer promise for fibrosis quantification but require further validation.

Treatment & Management

Current management of renal fibrosis is largely supportive, focusing on controlling underlying disease processes—glycemic and blood pressure control, renin-angiotensin system blockade, and minimizing nephrotoxin exposure. No approved therapies directly reverse fibrosis. Anti-fibrotic agents such as pirfenidone and pentoxifylline have shown limited efficacy. Given the central role of gene expression in fibrogenesis, RNA therapeutics offer a novel approach to modulate disease mechanisms more precisely than conventional therapies.

Recent Advances / Emerging Therapies

RNA-based therapeutics have rapidly advanced from bench to bedside in several disciplines. In renal fibrosis, siRNAs targeting TGF-β1, PDGFR-β, and CTGF have demonstrated significant reduction of fibrosis in preclinical models by downregulating key fibrogenic genes. ASOs against pro-fibrotic mRNAs (e.g., PAI-1, COL1A1) have shown efficacy in reducing ECM accumulation and improving renal histology. Modulation of miRNAs, especially inhibition of pathogenic miR-21 and restoration of anti-fibrotic miR-29, holds promise based on robust animal data. Delivery systems such as lipid nanoparticles and conjugates (e.g., N-acetylgalactosamine) enhance renal targeting and efficacy. Early-phase clinical trials are underway to assess safety, pharmacokinetics, and preliminary efficacy of these agents in CKD patients.

Guideline Recommendations

Current guidelines from KDIGO and other nephrology societies do not include RNA therapeutics in standard management due to the investigational nature of these interventions. However, they recognize the importance of enrolling patients in clinical trials and recommend close monitoring of novel agents for efficacy and safety. As more data emerge, future guideline updates may incorporate RNA therapies, particularly for patients with progressive fibrosis unresponsive to conventional treatments.

Conclusion

RNA therapeutics represent a transformative approach in the management of renal fibrosis, targeting the molecular drivers of fibrogenesis with unprecedented specificity. While clinical translation faces challenges related to delivery, durability, immunogenicity, and off-target effects, ongoing research and early clinical trials are highly encouraging. Integration of RNA-based therapies into nephrology practice has the potential to shift the paradigm from supportive care to disease modification, ultimately improving outcomes for patients with CKD. Continued collaboration between basic scientists, clinicians, and regulatory agencies will be critical to realize the full potential of RNA therapeutics in renal fibrosis.